JCJixuan Chen

Jixuan Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jixuan Chen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Bolun Zhu

    Department of General Surgery, Hepatobiliary Surgery Center, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China

    1 shared publication
  • Fangyuan Ding

    Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China

    1 shared publication
  • Feng Zhang

    National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China

    1 shared publication
  • Haichang Wang

    Queen Mary School, Nanchang University, Nanchang 330031, China

    1 shared publication
  • Hao Wang

    Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China; Cancer Metastasis Institute, Fudan University, Shanghai, China

    1 shared publication
  • Jiaqi Meng

    Third Affiliated Hospital of Naval Medical University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    A Lymphoid-Enriched Spatial Immune Niche Defines an Immunotherapy-Responsive State in Hepatocellular Carcinoma

    by Mingxiu Cai, Kaiheng Hu, Haichang Wang, Jing Li, Yiqi Wu, Qirui Han, Jixuan Chen, Wei Zhong, Xiangfan Huang, Fangyuan Ding, et al.

    Background: Atezolizumab plus bevacizumab is a first-line therapy for advanced hepatocellular carcinoma (HCC), yet only a subset of patients achieve durable benefit. The spatial organization of the tumour microenvironment (TME) and its relationship to immunotherapy response remain incompletely understood. Methods: We integrated single-cell transcriptomics, spatial transcriptomics, spatial proteomics, and bulk RNA-sequencing cohorts to characterize spatially organized immune ecosystems associated with immunotherapy response in HCC. Single-cell RNA sequencing from 100 HCC samples was used to construct a cellular reference, which was integrated with spatial transcriptomics from 12 sections to identify nine consensus spatial niches. Results: Niche 9 represented a lymphoid-enriched immune state characterized by B cells, plasma cells, natural killer cells, T-cell subsets, macrophages, and tertiary lymphoid structure-associated transcriptional features. Independent validation in a pretreatment, response-annotated Visium cohort showed enrichment of Niche 9-associated transcriptional activity in immunotherapy responders, while spatially co-registered 51-plex CODEX profiling provided orthogonal protein-level support for its lymphoid and immune-enriched phenotype. Multi-omics characterization further revealed coordinated immune-cell localization, ligand–receptor-associated patterns, and distinct metabolic programmes, with MEI1-positive plasma cells displaying enhanced secretory and stress-adaptation states. A nine-gene transcriptional signature derived from Niche 9 was associated with atezolizumab-plus-bevacizumab response, enhanced lymphoid immune features, lower Tumour Immune Dysfunction and Exclusion scores, and favourable clinical outcomes in independent cohorts. Conclusions: These multi-cohort and multi-omics analyses define a spatially derived lymphoid-enriched immune programme and link its molecular features to immunotherapy sensitivity in HCC.

  • Open Access

    Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma

    by Xin Zheng, Luyu Yang, Xiaotian Shen, Junjie Pan, Yiran Chen, Jixuan Chen, Hao Wang, Jiaqi Meng, Zhenchao Chen, Sunzhe Xie, et al.

    Background: Immune escape is an important feature of hepatocellular carcinoma (HCC). The overall response rate of immune checkpoint inhibitors (ICIs) in HCC is still limited. Revealing the immune regulation mechanisms and finding new immune targets are expected to further improve the efficacy of immunotherapy. Our study aims to use CRISPR screening mice models to identify potential targets that play a critical role in HCC immune evasion and further explore their value in improving immunotherapy. Methods: We performed CRISPR screening in two mice models with different immune backgrounds (C57BL/6 and NPG mice) and identified the immunosuppressive gene Gsk3a as a candidate for further investigation. Flow cytometry was used to analyze the impact of Gsk3a on immune cell infiltration and T-cell function. RNA sequencing was used to identify the changes in neutrophil gene expression induced by Gsk3a and alterations in downstream molecules. The therapeutic value of the combination of Gsk3a inhibitors and anti-programmed cell death protein-1 (PD-1) antibody was also explored. Results: Gsk3a, as an immune inhibitory target, significantly promoted tumor growth in immunocompetent mice rather than immune-deficient mice. Gsk3a inhibited cytotoxic T lymphocytes (CTLs) function by inducing neutrophil chemotaxis. Gsk3a promoted self-chemotaxis of neutrophil expression profiles and neutrophil extracellular traps (NETs) formation to block T-cell activity through leucine-rich α-2-glycoprotein 1 (LRG1). A significant synergistic effect was observed when Gsk3a inhibitor was in combination with anti-PD-1 antibody. Conclusions: We identified a potential HCC immune evasion target, Gsk3a, through CRISPR screening. Gsk3a induces neutrophil recruitment and NETs formation through the intermediate molecule LRG1, leading to the inhibition of CTLs function. Targeting Gsk3a can enhance CTLs function and improve the efficacy of ICIs.